The current status of breast cancer chemoprevention: A star is born

Journal of Surgical Oncology

Volumn 95, Issue 1, 2007, Pages 4-5

  Morrow, Monica ^a,b   Jordan, V Craig ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

BREAST CANCER; CANCER PREVENTION; CANCER RISK; CATARACT; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; HIGH RISK PATIENT; HUMAN; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK REDUCTION; THROMBOEMBOLISM;

EID: 33846310766     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.20658     Document Type: Editorial

References (5)

1. Fisher B, Costantino JP, Wickerham DL, et al.: Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005;97:1652-1662.
2. Tchou J, Hou N, Rademaker A, et al.: Acceptance of tamoxifen chemoprevention by physicians and women at risk. Cancer 2004;100:1800-1806.
3. Jordan VC: Selective estrogen receptor modulation: A personal perspective. Cancer Res 2001;61:5683-5687.
4. Vogel VG, Costantino JP, Wickerham DL, et al.: Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-2741.
5. Martino S, Cauley JA, Barrett-Connor E, et al.: Continuing outcomes relevant to Evista: Breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004;96:1751-1761.